Wyeth: The Protonix Hospital Deal That Left Medicaid Out

In the Wyeth Protonix Medicaid rebate settlement, Wyeth and Pfizer agreed to pay $784.6 million over allegations that Wyeth concealed bundled hospital discounts and underpaid Medicaid rebates. The alleged bargain reached beyond the hospital: discount oral and intravenous Protonix together, encourage hospitals to choose the oral drug, and keep the prescriptions coming after patients went home. The government said the hospital discounts never reached Medicaid’s reported prices. Someone who knew the sales offer and someone who knew the pricing calculation could see different parts of the same deal.

The Justice Department announced the settlement on April 27, 2016. This pharmaceutical fraud case concerned rebates allegedly avoided from 2001 through 2006. Pfizer acquired Wyeth in 2009, after the alleged scheme ended.

The agreement allocated $413,248,820 to the federal government and $371,351,180 to state Medicaid programs.

How the Wyeth Protonix Hospital Bundle Worked

The Wyeth Protonix hospital bundle allegedly linked discounts on Protonix Oral and Protonix IV to induce hospitals to use the oral product. Both were proton pump inhibitors. The whistleblowers brought the case, and the government pursued allegations of deep discounts to thousands of hospitals.

The hospital already had reasons to choose competing oral drugs. According to the government’s account, those products were competitively priced and considered at least as effective and safe. Wyeth allegedly used the linked oral and intravenous offer to give hospitals a financial reason to choose Protonix Oral anyway.

The commercial prize was the prescription that followed the patient home. The government said patients discharged on Protonix Oral were likely to stay on it for long periods, while Medicaid and other health care payers paid nearly full price.

It also explains the taxpayer’s stake. Medicaid’s rebate was supposed to carry qualifying commercial discounts into what the program ultimately paid. The government alleged that Wyeth kept the hospital incentive working while leaving its value out of the rebate calculation. In the government’s account, hospitals got the deal and Wyeth pursued the continuing business, while taxpayers lost the rebate benefit.

How Best Price Turned the Hospital Offer Into a Medicaid Rebate

Medicaid Best Price is the lowest qualifying price a manufacturer makes available to specified purchasers during the rebate period. Qualifying discounts include cash discounts, volume discounts, rebates and free goods contingent on purchases. The commercial terms matter because the price after concessions can differ sharply from the price before them.

Under the Medicaid Drug Rebate Program, manufacturers report average manufacturer price and Best Price to the government. The basic rebate for brand drugs compares the difference between those prices with a minimum percentage rebate and uses whichever is greater. States supply the Medicaid utilization to which the rebate applies. A qualifying lower Best Price can therefore increase the rebate owed on Medicaid purchases.

For Protonix, the alleged missing input was the concession earned through the linked hospital offer. The government said Wyeth concealed that concession and avoided hundreds of millions of dollars in rebates. A discount given to a private hospital mattered to the public program because it belonged in the manufacturer’s pricing calculation.

The allocation question follows the bargain. Which products did the hospital have to purchase, and what commitments earned the discount? A bundled concession is allocated across the products in proportion to their share of the arrangement’s total dollar sales. Separating the oral and intravenous products on an invoice does not explain how the linked offer was treated in Best Price.

For a pricing employee, the important comparison is between the concession the hospital actually earned and the concession included in the reported price. That is where this Best Price allegation becomes more specific than a general complaint about expensive drugs. The government identified a discount available to a commercial buyer and said Medicaid lost the rebate benefit.

A Large Discount Can Accompany a High Price

A later industry study shows why the word rebate alone tells so little about the price someone ultimately pays. The USC Schaeffer Center’s 2020 white paper The Association Between Drug Rebates and List Prices examined 1,335 U.S. brand prescription drugs by National Drug Code from 2015 through 2018. It found that increases in estimated rebates were associated with increases in list prices, including after excluding drugs with high Medicaid spending shares.

A large aggregate rebate figure does not tell us which customer earned which concession or how a manufacturer treated it for Medicaid. The contract and the calculation supply that detail.

What Evidence Is Needed to Prove Fraud?

For an alleged Protonix-style omission, the evidence needs to connect the hospital’s purchasing terms to the manufacturer’s Best Price calculation, reported price and rebate payment. Our work with an insider starts with those connections.

The hospital agreement describes the offer: which drugs belong in it, what purchasing commitments earn the concession, and what changes when the hospital meets those commitments. Purchase and discount records show the terms put into practice. In the Wyeth allegations, the connection between oral and intravenous discounts was the reason those records had to be understood together.

The pricing calculation answers a different question: where did the concession go? We compare the transaction with the calculation’s treatment of the discount, the products included in the allocation and the price ultimately reported. A hospital contracting employee may understand why the offer was attractive. A government pricing employee may understand why the same offer produced no corresponding change in Best Price.

Price reports require certification by a senior officer or an authorized delegate. The comparison therefore extends from the commercial offer to the calculation, its supporting assumptions and the certified report. For an employee who questioned a particular discount’s treatment, the decision about that treatment can be as revealing as the discount itself.

If a company later changes its pricing assumptions or restates a price, we examine what changed and which transactions it affected. We work with the person who understands the decision inside the business, connecting that account to the rebate the government should have received. This is where contracting, pricing and finance knowledge can turn a discrepancy into a coherent case.

Who Brought the Protonix Rebate Case?

Two whistleblowers brought the allegations resolved by the Protonix settlement: a physician and a former hospital sales representative for AstraZeneca. The sales representative had worked for a different pharmaceutical company, a useful fact for someone who knows a competitor’s hospital offer better than the competitor expects.

The physician also brought the Merck Pepcid pricing case. The connection between those matters is commercial as well as personal: both concerned hospital discounts intended to win continued drug use after discharge, with allegations that the discounts were omitted from government price reporting.

These roles show why a pricing case can begin beyond the manufacturer’s government reporting department. A clinician or hospital sales employee can recognize the purchasing arrangement. A pricing employee can explain how an arrangement enters the reported number.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The Protonix settlement terms provided for the whistleblowers’ combined federal and state share of approximately $98 million.

That was the share for the two whistleblowers together. The qui tam cases they brought put the alleged hospital discount omission before the government.

Merck’s Hospital Discounts Sought the Same Outpatient Business

Merck’s 2008 Pepcid settlement addressed a similar allegation: reduced hospital prices intended to secure continued purchases after discharge. In the Justice Department’s account of the Merck cases, hospitals allegedly received substantially reduced Pepcid prices when they agreed to favor it over a competing drug. The government said Merck sought the later business from patients who continued using Pepcid at home.

The separate Zocor and Vioxx allegations concerned deep discounts tied to hospitals using large quantities instead of competing brands. Across the Pepcid, Zocor and Vioxx cases, the government alleged that Merck labeled hospital prices nominal and excluded the discounts from its reports.

That is the link to nominal pricing and Medicaid rebates. Merck’s alleged reporting treatment turned on an exclusion claimed for a very low price. Wyeth’s turned on the treatment of linked discounts. Both accounts describe a manufacturer paying for hospital preference while allegedly keeping the qualifying concession out of the government’s price calculation.

The contract’s commercial purpose is often easier to recognize than the accounting treatment. A hospital sales employee knows what the buyer has to do to earn the offer. That knowledge gives a pricing investigator something concrete to compare with the reported number.

The Purchasing Condition Can Be Written Into the Contract

A whistleblower’s complaint against Astellas gives a particularly clear example of an alleged hospital purchasing condition. It described discounts on Mycamine tied to children’s hospitals’ use of the drug:

The purchasing target and the pricing consequence make the condition visible. That complaint illustrates the hospital contracting side of the comparison. In Protonix, the additional government allegation was that linked hospital discounts were hidden from Medicaid. Connecting the offer to the price report is what makes the rebate issue understandable.

The Separate Protonix Promotion Payment

Pfizer’s December 12, 2012 Protonix resolution was a separate $55 million civil payment over alleged improper promotion and sales of misbranded Protonix. The government alleged that Wyeth promoted the drug for unapproved uses.

You Know Why the Hospital Got That Price

If you know the purchasing condition behind a hospital discount or the decision that kept it out of Medicaid reporting, speak with our whistleblower experts. We develop the healthcare pricing case with you and bring in pharmaceutical pricing whistleblower lawyers who understand bundled concessions and Medicaid rebates. From the first explanation of the deal through the pursuit of recovery, we stay on your side of the table.